Regenerative Medicine Projects: 3-D Tissue Chips
McGowan Institute for Regenerative Medicine associate director Rocky Tuan, PhD, and fellow researchers at the University of Pittsburgh School of Medicine have been awarded federal grants to create micro-models of an arthritic joint and the liver as part of a national effort to build 3-D chips of cells and tissues that could provide a more rapid and accurate method of predicting toxicity of experimental therapies, as well as foster greater understanding of myriad diseases.
Of the 17 projects being funded by the National Institutes of Health (NIH), two will be led by Pitt researchers and could receive more than $10 million over the next 5 years. NIH plans to commit up to $70 million over 5 years for the Tissue Chips for Drug Screening program, which was launched by its new National Center for Advancing Translational Sciences (NCATS). Other awardees include Johns Hopkins University, Harvard University, and Duke University.
“Tissue chips could provide a more accurate and less expensive way of testing new drugs and reduce our reliance on animal studies, which often don’t reliably reflect toxicity profiles later seen during human testing,” noted Arthur S. Levine, M.D., senior vice chancellor for the health sciences and dean, Pitt School of Medicine. “It is terrific that our stellar scientists will be able to build two of these chips here and contribute to the evolution of drug testing.”
The Pitt projects are:
- 3-D Micro-Arthritic Joint System: Dr. Tuan, the Arthur J. Rooney Sr. Professor of Sports Medicine and executive vice chair for research, Department of Orthopaedic Surgery, will lead a team to create a tissue chip that includes stem cell-produced bone and cartilage cells that simulate joint surfaces to better understand how arthritis develops and how to prevent it.
“This system will allow us to explore the effects of not only inflammatory molecules and the wear-and-tear of aging on the entire joint, but also mechanical injuries, such as a hit or a sprain, both immediately and over time in molecular detail, which is not feasible with existing techniques,” said Dr. Tuan, who also is director of the Center for Military Medicine Research and director of the Center for Cellular and Molecular Engineering in the Department of Orthopaedic Surgery.
- 3-D Micro-Liver: D. Lansing Taylor, PhD, Allegheny Foundation Professor of Computational and Systems Biology, and director, University of Pittsburgh Drug Discovery Institute, will lead a team at Pitt and Massachusetts General Hospital to create a three-dimensional microfluidic structure made entirely of human cells that will mimic the acinus, the smallest functional unit of the liver. The team also will develop a panel of sentinel “biosensor cells” that will indicate liver toxicity with exposure to different drugs.
“The current gold standard of testing is not very gold,” Dr. Taylor said. “In humans, the liver plays a key role in processing drugs, and many experimental agents have failed in the late stages of human testing because preclinical studies didn’t predict their impact on the liver, along with other organs. This project aims to solve that problem so that we have greater success in drug discovery and development.”
According to NIH, the Tissue Chips program is the result of collaboration between NIH, the Defense Advanced Research Projects Agency (DARPA), and the U.S. Food and Drug Administration, and was established by the NIH’s Common Fund and the National Institute of Neurological Disorders and Stroke.
“Serious adverse effects and toxicity are major obstacles in the drug development process,” said Thomas R. Insel, M.D., NCATS acting director. “With innovative tools and methodologies, such as those developed by the Tissue Chips program, we may be able to accelerate the process by which we identify compounds likely to be safe in humans, saving time and money, and ultimately increasing the quality and number of therapies available for patients.”
Drs. Tuan and Taylor’s projects also will receive support from the University of Pittsburgh Clinical and Translational Science Institute.